Use of systemic therapies for psoriasis in the COVID-19 era
Background In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis. Objective The purpose of this review is to analyze what is currently known...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1775774 |
| _version_ | 1797683609062080512 |
|---|---|
| author | Donovan G. Kearns Shelley Uppal Vipawee S. Chat Jashin J. Wu |
| author_facet | Donovan G. Kearns Shelley Uppal Vipawee S. Chat Jashin J. Wu |
| author_sort | Donovan G. Kearns |
| collection | DOAJ |
| description | Background In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis. Objective The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic. Methods Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized. Results The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy. Conclusion Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis. |
| first_indexed | 2024-03-12T00:16:58Z |
| format | Article |
| id | doaj.art-5fea30905b284fd4a89e5ab1c7ed261c |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:16:58Z |
| publishDate | 2022-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5fea30905b284fd4a89e5ab1c7ed261c2023-09-15T14:23:06ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-02-0133262262510.1080/09546634.2020.17757741775774Use of systemic therapies for psoriasis in the COVID-19 eraDonovan G. Kearns0Shelley Uppal1Vipawee S. Chat2Jashin J. Wu3Loma Linda University School of MedicineAlbany Medical CollegeMedical College of Georgia at Augusta UniversityDermatology Research and Education FoundationBackground In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis. Objective The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic. Methods Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized. Results The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy. Conclusion Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis.http://dx.doi.org/10.1080/09546634.2020.1775774covid-19biologicsystemic treatmentimmunosuppressantpsoriasis |
| spellingShingle | Donovan G. Kearns Shelley Uppal Vipawee S. Chat Jashin J. Wu Use of systemic therapies for psoriasis in the COVID-19 era Journal of Dermatological Treatment covid-19 biologic systemic treatment immunosuppressant psoriasis |
| title | Use of systemic therapies for psoriasis in the COVID-19 era |
| title_full | Use of systemic therapies for psoriasis in the COVID-19 era |
| title_fullStr | Use of systemic therapies for psoriasis in the COVID-19 era |
| title_full_unstemmed | Use of systemic therapies for psoriasis in the COVID-19 era |
| title_short | Use of systemic therapies for psoriasis in the COVID-19 era |
| title_sort | use of systemic therapies for psoriasis in the covid 19 era |
| topic | covid-19 biologic systemic treatment immunosuppressant psoriasis |
| url | http://dx.doi.org/10.1080/09546634.2020.1775774 |
| work_keys_str_mv | AT donovangkearns useofsystemictherapiesforpsoriasisinthecovid19era AT shelleyuppal useofsystemictherapiesforpsoriasisinthecovid19era AT vipaweeschat useofsystemictherapiesforpsoriasisinthecovid19era AT jashinjwu useofsystemictherapiesforpsoriasisinthecovid19era |